PaperPaper Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting External Link Read MorePaper XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma PDF (5.34 MB) Read MorePaper The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia PDF (3.69 MB) Read MorePaper Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death PDF (2.61 MB) Read MorePaper Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone PDF (2.41 MB) Read MorePaper Inhibition of the nuclear export receptor xpo1 as a therapeutic target for platinum resistant ovarian cancer PDF (6.21 MB) Read MorePaper Heterozygous mutation of cysteine 528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export PDF (3.10 MB) Read MorePaper ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization PDF (3.00 MB) Read MorePaper Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors PDF (86.77 KB) Read MorePaper Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia PDF (2.13 MB) Read More Previous 1 2 3 4 5 … 7 Next